Previous 10 | Next 10 |
2023-11-01 14:00:24 ET More on Curis Curis, Inc. (CRIS) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Curis Historical earnings data for Curis Financial information for Curis For further details see: Curis Q3 2023 Earning...
2023-11-01 11:48:22 ET Major earnings expected before the bell on Thursday include: Barrick Gold ( GOLD ) Moderna ( MRNA ) Palantir Technologies ( PLTR ) Starbucks ( SBUX ) Shopify ( SHOP ) For further details see: Notable earnings before ...
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 PR Newswire LEXINGTON, Mass. , Oct. 26, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orall...
2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer PR Newswire Symposium hosted by Guillermo Garcia-Manero, M.D. and Eric Winer, M.D. Academics and industry professionals will gather virtually on September 22, 2023 LEXINGTON, Mass. ...
2023-08-03 21:35:25 ET Curis, Inc. (CRIS) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Diantha Duvall – Chief Financial Officer Jim Dentzer – President and Chief Executive Officer Conference Call Participants ...
2023-08-03 16:23:50 ET Curis press release ( NASDAQ: CRIS ): Q2 GAAP EPS of -$0.12 in-line. Revenue of $2.2M (-7.9% Y/Y) misses by $0.31M . Shares -1.56% . For further details see: Curis GAAP EPS of -$0.12 in-line, revenue of $2.2M misses by $0.31M
Curis Provides Second Quarter 2023 Business Update PR Newswire Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong bal...
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 PR Newswire LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally...
2023-07-24 19:15:20 ET Summary Curis, a microcap biotech company, is focusing on the development of cancer drugs, currently supporting six drug trials with a burn rate of over $30 million per year. Despite a recent direct offering adding $15.1 million to its balance sheet and a lo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...